On July 18, the Government Accountability Office (GAO) issued a report that compares characteristics of hospitals participating in the 340 Drug Pricing Program with those not participating in the 340B Program. The report focuses on three types of hospitals that made up more than 95 percent of 340B participants in 2016.
The report examines the effects of Medicaid expansion on 340B participation and other characteristics such as rates of charity care provided.
Because for certain types of hospitals 340B eligibility is partially based on the number of Medicaid patients served, the report finds that 340B participation increased for those particular hospitals in states that expanded Medicaid.
Read the report summary.
View the full report.
Posted 07/25/18
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
